AstraZeneca, Pfizer, Gilead release cancer drug data

A version of this text first appeared in CNBC’s Healthy Returns newsletter, which brings the most recent health-care news straight to your inbox. Subscribe here to receive future editions.

I’m back in Recent York City after spending the last weekend in Chicago for the American Society of Clinical Oncology annual meeting.

Greater than 5,000 research abstracts were presented or published at ASCO by pharmaceutical giants, biotech firms, researchers and oncologists. They included studies on existing drugs, experimental treatments, AI tools and concepts for improving patient care. 

Listed below are some data highlights and executive commentary from the larger firms I follow: 

AstraZeneca wins big (again) – The blockbuster drug Enhertu from AstraZeneca and Japanese drugmaker Daiichi Sankyo stalled the expansion of a standard sort of breast cancer by greater than a yr in a big late-stage trial when used as an initial treatment. The outcomes could expand using the drug and alter the best way the disease is treated for the primary time in a decade. 

The study evaluated Enhertu together with a normal medicine called pertuzumab as a frontline treatment, meaning it was utilized in patients newly diagnosed with what’s generally known as HER2-positive metastatic breast cancer. Patients who got the Enhertu combination lived for nearly 41 months before their disease spread, while a gaggle who received a normal three-drug treatment lived for about 27 months before the cancer advanced.

David Fredrickson, executive vice chairman of AstraZeneca’s oncology business, told CNBC that one in three patients who start treatment for this sort of cancer are usually not capable of receive a second sort of therapy because their health worsened or they died.

But the outcomes show that the Enhertu combination could give “one other third of patients a likelihood to potentially have an extended progression-free survival time and to learn from a more practical frontline therapy than for those who wait till a second one.”

Pfizer impresses in colorectal cancer – The corporate’s pill Braftovi, combined with two other cancer treatments, doubled survival time for patients with an aggressive type of colorectal cancer in comparison with a normal treatment in a late-stage trial. It’s excellent news for Pfizer, which has submitted the info to the Food and Drug Administration to expand Braftovi’s approval label. 

The three-treatment combination included a normal chemotherapy, an antibody drug called cetuximab and Braftovi, which targets a cancer mutation called BRAF V600E. That combination also cut deaths by 51% and slashed the danger that the cancer would progress by 47% in comparison with a normal treatment throughout the trial. 

Pfizer’s Chief Scientific Officer Chris Boshoff told CNBC that 10% to fifteen% of colorectal cancer patients have that specific mutation, and noted their survival rates are “particularly poor.”

“We’re very pleased with [the data] because for the primary time, it really shows a real impact on survival for a disease that is very difficult to treat,” he said. 

Gilead and Merck combo’s breast cancer win — The favored drug Trodelvy from Gilead together with Merck’s blockbuster immunotherapy Keytruda lowered the danger of an aggressive sort of breast cancer worsening by 35% when used as an initial treatment in a late-stage trial. Gilead may gain advantage from higher sales of Trodelvy because it competes with Enhertu. 

The study examined patients with advanced triple-negative breast cancer whose tumors express PD-L1, the protein targeted by drugs like Keytruda. Around 15% of breast cancer cases are triple negative, making them more aggressive and difficult to treat, in accordance with Gilead. 

The findings suggest that the mix of Trodelvy and Keytruda “will likely develop into a brand new front-line standard of care on this setting,” Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a chosen ASCO expert, said in a press release.

A Merck, Daiichi Sankyo drug disappoints in lung cancer  – Merck and Daiichi Sankyo on Thursday said they’ve withdrawn their U.S. application for an experimental treatment after it didn’t delay the lives of lung cancer patients in a late-stage trial. 

The drug, patritumab deruxtecan, is certainly one of three so-called antibody drug conjugates that Merck has been working on with Daiichi Sankyo because it races to offset Keytruda’s upcoming lack of exclusivity. 

The medication failed the trial’s secondary goal of extending overall survival, which is defined because the length of time patients lived from the beginning of treatment. Those results, together with subsequent discussions with the FDA, led the businesses to withdraw the appliance. 

But last yr, the drug met the study’s principal goal of helping delay tumor progression in comparison with chemotherapy in patients who’ve been previously treated for non-small cell lung cancer with a mutation in a gene called EGFR. 

Marjorie Greene, Merck’s head of oncology global clinical development, told CNBC that the “totality of the info couldn’t support” the drug’s application for approval. She called it a disappointment but noted that the corporate is learning from “what worked and what didn’t work” and remains to be “fully investing” in refining the drug. 

Merck and Daiichi Sankyo plan on advancing the treatment right into a late-stage development for breast cancer. 

Amgen‘s positive lung cancer data: The corporate’s drug, Imdelltra, reduced the danger of death by 40% in comparison with chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemotherapy, in accordance with data from a late-stage trial. 

Imdelltra also prolonged median overall survival by greater than five months in comparison with the standard-of-care chemotherapy. 

Amgen said the trial results are intended to support last yr’s accelerated approval of Imdelltra by the FDA. 

BONUS: Bristol Myers Squibb inks take care of BioNTech – Bristol Myers Squibb on Monday said it has agreed to pay as much as $11.1 billion to partner with BioNTech and develop its next-generation cancer immunotherapy. 

The drug could tackle Keytruda and recent treatments in development by Summit Therapeutics and Pfizer. BioNTech is running late-stage studies on the drug in lung cancer and plans to start out a phase three trial in triple-negative breast cancer this yr.

Be at liberty to send any suggestions, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.

Be at liberty to send any suggestions, suggestions, story ideas and data to Bertha at bertha.coombs@nbcuni.com.

Amazon Pharmacy on Tuesday announced recent updates for caregivers and greater than 50 million Medicare Part D beneficiaries. 

Read the total announcement here. 

Be at liberty to send any suggestions, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.